Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28400651 | 0.95 | EPHX1 (0.44) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| Magnesium Chloride Anhydrous SCHEMBL28400650 | 0.93 | EPHX1 (0.43) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL14667804 | 0.87 | SIGMAR1 (0.48) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL935835 | 0.81 | TAAR1 (0.46) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL8194993 | 0.79 | EPHX1 (0.43) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL14667806 | 0.79 | TSHR (0.46) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL14667805 | 0.78 | TAAR1 (0.43) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL31618519 | 0.76 | SRR (0.43) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL9118343 | 0.76 | TAAR1 (0.42) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL8194995 | 0.76 | SRR (0.42) | EPHX1TAAR1SLC6A2SIGMAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118202009-A | Ink applicator | 墨水盒墨水公司 | 2024-06-14 | — | — | CN | claimed |
| WO-1998051659-A1 | SALICYLOXY α-CARBOXY ACIDS AND PREPARATION THEREOF | UNILEVER PLC (GB) | 1998-11-19 | — | — | WO | claimed |
| US-20260130904-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-05-14 | — | — | US | disclosed |
| EP-3911640-B1 | PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE | ASTRAZENECA AB (SE) | 2026-05-13 | — | — | EP | disclosed |
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2026-04-28 | — | — | US | disclosed |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-03-24 | — | — | US | disclosed |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-02-17 | — | — | US | disclosed |
| US-20250339411-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | CHONGQING PHARMACEUTICAL RES INSTITUTE CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| US-12419874-B2 | GLP-1R agonist compound and use thereof | CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2025-09-23 | — | — | US | disclosed |
| EP-4612156-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4605386-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-0223437-A2 | Aminocarbonyl renin inhibitors | E.R. Squibb & Sons, Inc. (US) | 1987-05-27 | — | — | EP | disclosed |
| US-4668814-A | ANTIULCER AGENTS, ANTIASHMATICS, ANTICOAGULANTS | THE UPJOHN COMPANY (US) | 1987-05-26 | — | — | US | disclosed |
| US-4624951-A | Substituted pyridazinones, pharmaceutical preparations containing these compounds, and the use thereof | CIBA-GEIGY CORPORATION (US) | 1986-11-25 | — | — | US | disclosed |
| EP-0159784-A1 | Carbacyclin analogues | THE UPJOHN COMPANY (US) | 1985-10-30 | — | — | EP | disclosed |
| EP-0126506-A2 | Preparation of the alkyl cyclopentane-carboxylates useful as intermediates for preparing prostaglandins | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1984-11-28 | — | — | EP | disclosed |
| EP-0094065-A2 | 2-Aminobenzoic acid derivatives, a process for their preparation and pharmaceutical compositions | FERRER INTERNACIONAL, S.A. (ES) | 1983-11-16 | — | — | EP | disclosed |
| EP-0000453-B1 | PROCESS FOR THE PREPARATION OF THIENOPYRIDINE DERIVATIVES. | OMNIUM FINANCIER AQUITAINE POUR L'HYGIENE ET LA SANTE - SANOFI (FR) | 1980-07-23 | — | — | EP | disclosed |
| US-4198421-A | ANTIARTHRITIC | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-04-15 | — | — | US | disclosed |
| EP-0000453-A1 | Process for the preparation of thienopyridine derivatives. | OMNIUM FINANCIER AQUITAINE POUR L'HYGIENE ET LA SANTE - SANOFI (FR) | 1979-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | CASP6, CASP3, BAX | EPHX1 4118/4885TAAR1 1089/4885SLC6A2 2150/4885 |
| US-20260130904-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | EBP, SIGMAR1, EP300 | EPHX1 1318/4885TAAR1 181/4885SLC6A2 477/4885 |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | EPHX1 652/4885TAAR1 3523/4885SLC6A2 1359/4885 |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, LDLR, PCSK7 | EPHX1 3511/4885TAAR1 3228/4885SLC6A2 263/4885 |
| US-20250339411-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | GLP1R, GIPR, GPR119 | EPHX1 4003/4885TAAR1 344/4885SLC6A2 467/4885 |
| US-12419874-B2 | GLP-1R agonist compound and use thereof | GLP1R, GIPR, GPR119 | EPHX1 4003/4885TAAR1 344/4885SLC6A2 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.